News

Highly variable myopia shifts can occur in pseudophakic children. IOL exchange seems to be an acceptable option for treating the high myopia that can develop with lens implantation in children.However, the use of IOLs in growing eyes remains controversial, and outcomes are uncertain because of lack of data, according to Courtney Kraus, MD.

The role of science and theory behind the nutritional influences on dry eye disease is explored by the co-authors.

A more comprehensive, meticulous approach to the assessment and treatment of chronic dry eye may improve its management and prevent ocular injury and damage resulting from delays in care.

A new device provides dynamic images of the meibomian glands and allows ophthalmologists to assess meibomian gland health and function from a new perspective.

Vernon Benjamin Mountcastle, MD-recipient of the Lasker Award and the National Medal of Science-was the first person to understand how the cells in the higher regions of the brain are organized, earning him the nickname of "the Jacques Cousteau of the [cerebral] cortex." He was the first president of the Society for Neuroscience and editor of the Journal of Neurophysiology.

Olopatadine 0.2% is a well-tolerated, safe, and effective antihistamine/mast cell stabilizer for treating mild to severe allergic conjunctivitis in children and adults.

Overcoming objections is one of the most difficult techniques for opticians (and most salespeople) to master.

Transgenic mice engineered to have extra copies of the TBK1 gene showed effects similar to those in human patients with normal-tension glaucoma, providing clues to pathophysiology and potential treatments.

A novel dexamethasone-eluting punctum plug was safe and showed some evidence of efficacy for relieving signs and symptoms of allergic conjunctivitis in a phase II study.

Treatment based on the findings of a thorough history, appropriate testing, and clinical exam can be successful for bringing relief to many problem dry eye patients.

Joseph Tauber, MD, offers a critical appraisal of the role of available point-of-care tests for evaluating dry eye.

Spectral-domain optical coherence tomography is useful for diagnosing early keratoconus because it detects characteristic changes in epithelial and stromal thickness.

Mitomycin C, when used in accordance with the approved guidelines, can be beneficial but can cause haze with long exposures and higher concentrations.

Intraoperative aberrometry may reduce refractive surprises and result in a higher percentage of happy patients following cataract surgery, particularly those who had undergone previous corneal refractive surgery and in those planning for a toric IOL.

Ocular surface disease and health are affected by numerous interactions and cascades with complex mechanisms in disease states.

In head-to-head clinical assessments, alcaftadine was found to be statistically and clinically superior to olopatadine for relief of allergic conjunctivitis.

A recent study explored the potential of a novel ophthalmic emulsion in dry eye subjects dosed twice daily for 2 weeks.

A topical epithelial sodium channel blocker is being investigated in a phase I/IIa clinical trial as a novel treatment for dry eye disease.

A number of clinical trials are focusing on various medical uses for contact lenses. The latest updates on these and other studies are always accessible via clinicaltrials.gov.

Corneal confocal microscopy (CCM) has been found to predict peripheral neuropathy in patients with type 1 diabetes, according to a recent study.

The FDA has approved Genentech’s ranibizumab injection (Lucentis) for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME).

Answer lies in attention to candidate selection, counseling, and IOL positioning

New technology can help ophthalmologists care for their patients if they combine it with a personal touch, said Paul P. Lee, MD, JD, in the Shaffer-Hetherington-Hoskins Lecture during the Glaucoma 360 CME Symposium.

Even the best ophthalmologists must prepare to support patients who lose vision while in their care, said Robert L. Stamper, MD.

Insurers are funneling patients to providers based on cost and quality data that may not always be accurate, said Ruth D. Williams, MD.

The development of stem cell treatments for glaucoma faces big hurdles, but researchers are making rapid progress, said Yvonne Ou, MD.

Gary D. Novack, PhD, president of PharmaLogic Development, co-moderated an industry panel discussion on glaucoma pharmaceuticals Friday during Glaucoma 360. Watch Dr. Novack outline the state of glaucoma drug therapy and where the future is headed.

A team of researchers may soon be able to catch glaucoma cases early by spotting nerve damage, said Andrew D. Huberman, PhD, as he provided an update on the work of the Glaucoma Research Foundation’s Catalyst for a Cure Biomarkers Initiative at the Glaucoma 360 New Horizons Forum.